ReviewContemporary oncology (Poznan, Poland)2024
Molecular landscape of salivary gland malignancies. What is already known?
Review in Contemporary oncology (Poznan, Poland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- MicroRNAs in Salivary Gland Cancers Associated with Poor Prognosis: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Metabolic Marker GLUT1 in Salivary Gland Cancers: Quantification and Effect-Size Estimation.Biomedicines · 2026Article
- Evolving Concepts in Salivary Duct Carcinoma: A Narrative Review.Oncology and therapy · 2026Review
- SOX-2 and EZH-2 Expression in Primary Epithelial Malignant Salivary Gland Tumors.Medical sciences (Basel, Switzerland) · 2026Article
- Article
- Potentially actionable molecular alterations in particular related to poor oncologic outcomes in salivary gland carcinomas.BMC cancer · 2025Article
- Correction for: Molecular landscape of salivary gland malignancies. What is already known?Contemporary oncology (Poznan, Poland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Salivary gland carcinomas (SGCs) are highly heterogeneous histopathological entities that arise in either the major or minor salivary glands. Although uncommon, these tumours exhibit considerable aggressiveness, unpredictable progression, and significant mortality. The fifth edition of the World Health Organisation classification of head and neck tumours distinguishes between 24 salivary gland malignancies. This may lead to difficulties in terms of diagnostic accuracy and suitable therapeutic selection. Mucoepidermoid carcinoma occurs most frequently and is characterised by gradual disease progression. Although salivary duct carcinoma, myoepithelial carcinoma, and carcinoma ex pleomorphic adenoma are rarely detected, they contribute to poor patient outcomes. Currently, attempts have been made to establish molecular characterisation of SGCs to improve differential diagnosis and create targeted treatments. This study aimed to summarise current knowledge regarding genetic variations in the most common salivary gland malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.